Hygieia

Hygieia Pharmaceuticals Co., Ltd., located in Shanghai's Zhangjiang High-Tech Park, focuses on the research and development of drugs in the small interfering RNA (siRNA) field. The company is committed to leveraging various novel delivery platforms in the siRNA domain to address significant unmet clinical needs for serious diseases, benefiting patients. Hygieia currently holds more than 20 patents domestically and internationally and has developed proprietary siRNA delivery platforms, including the Nanoparticle Delivery Platform (NPDP), Multivalent Import Platform (MVIP), and Lipid-Conjugated Delivery Platform (LCDP). These three delivery platforms are world-class in terms of technology and quality. Additionally, more novel drug delivery platforms are under continuous development.